OCT 19, 2017 08:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
WEBINAR: New viral and non-viral platforms for T-cell engineering
SPONSORED BY: Thermo Fisher Scientific/Gibco
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
3 37 1835

Speakers:
  • Director, R&D, Cell Biology/Transfection at Thermo Fisher Scientific
    Biography
      Xavier de Mollerat du Jeu, Ph.D. is a Director of R&D transfection group at Thermo Fisher Scientific, working on creating and improving new nucleic acids delivery for both research and therapeutic applications. Xavier identified new DNA delivery approaches for hard to transfect cell lines and primary/stem cells and he is the inventor of Lipofectamine® 3000. Xavier's team is also focusing on new delivery solutions for CRISPR delivery, new scalable lentiviral production systems, mechanical delivery approaches for primary T cells and in vivo delivery of RNAi/mRNA for research and therapeutic application. He studied molecular biology and plant physiology at the University of Montpellier II in France, and received his Ph.D. in human genetics in 2003 from Clemson University in South Carolina. His thesis work involved identifying the gene(s) responsible for Split Hand/Split Foot Malformation 3 (SHFM 3). His post-doctoral fellowship research was in the laboratory of Dr. Michael G. Rosenfeld at UCSD, where he studied the roles of microRNAs in pituitary gland development. He joined Thermo Fisher in 2005.

    Abstract:

    DATE: October 19, 2017
    TIME: 08:00am PDT, 11:00am EDT

     

    Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:

    • New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System
      • Platform development process using Design of Experiment (DOE) methodologies
      • High-throughput to large scale bioreactor protocols
      • Cost benefits of this system over current methods
    • Novel gene editing tools for primary T cells
      • New potent gene editing tools to increase knock-in and knock-out efficiency
      • Addressing non-viral delivery barriers through protocol optimization

    Learning Objectives:

    • Current industry trends and challenges of cell and gene therapy manufacturing
    • Benefits of innovative new upstream technologies for virus generation in suspension

    Show Resources
    Loading Comments...